Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PEN 
Penumbra Inc (PEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/20/2025: PEN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Upturn Analyst’s Rating
18 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $281.13
| 12 | Strong Buy |
| 2 | Buy |
| 4 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 76.29% | Avg. Invested days 55 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 05/20/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.82B USD | Price to earnings Ratio 232.64 | 1Y Target Price 318.62 |
Price to earnings Ratio 232.64 | 1Y Target Price 318.62 | ||
Volume (30-day avg) 604824 | Beta 0.49 | 52 Weeks Range 148.00 - 310.00 | Updated Date 06/27/2025 |
52 Weeks Range 148.00 - 310.00 | Updated Date 06/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3.41% | Operating Margin (TTM) 12.45% |
Management Effectiveness
Return on Assets (TTM) 5.82% | Return on Equity (TTM) 3.5% |
Valuation
Trailing PE 232.64 | Forward PE 71.43 | Enterprise Value 9661930865 | Price to Sales(TTM) 7.92 |
Enterprise Value 9661930865 | Price to Sales(TTM) 7.92 | ||
Enterprise Value to Revenue 7.79 | Enterprise Value to EBITDA 133.02 | Shares Outstanding 38725900 | Shares Floating 37591657 |
Shares Outstanding 38725900 | Shares Floating 37591657 | ||
Percent Insiders 3.57 | Percent Institutions 91.83 |
Analyst Ratings
Rating 4.44 | Target Price 318.62 | Buy 2 | Strong Buy 12 |
Buy 2 | Strong Buy 12 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Penumbra Inc
Company Overview
History and Background
Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California. The company develops and markets medical devices addressing unmet needs in neurovascular and vascular diseases. It went public in 2015. Key milestones include the development of various thrombectomy devices and advancements in vascular embolization technologies.
Core Business Areas
- Neuro: Focuses on devices for treating neurovascular diseases, primarily stroke and aneurysm.
- Vascular: Develops and markets devices for peripheral vascular diseases, including thrombectomy and embolization.
Leadership and Structure
Adam Elsesser is the Chairman, President, and CEO. The company has a typical corporate structure with functional departments covering R&D, Sales & Marketing, Operations, and Finance.
Top Products and Market Share
Key Offerings
- Penumbra System: A thrombectomy system used to remove blood clots in stroke patients. Competitors include Medtronic and Stryker. Market share is estimated to be significant in certain segments of the stroke thrombectomy market but specific numbers are difficult to gather in aggregate.
- Indigo System: A continuous aspiration system for peripheral thrombectomy. Competitors include Boston Scientific and Philips.
- LANTERN Aneurysm Stent System: A stent system to treat cerebral aneurysms.
Market Dynamics
Industry Overview
The neurovascular and peripheral vascular device markets are characterized by technological innovation and increasing demand due to aging populations and lifestyle-related diseases.
Positioning
Penumbra is positioned as an innovator in its space, focusing on minimally invasive techniques. Its competitive advantage lies in its proprietary technology and clinical data supporting its devices.
Total Addressable Market (TAM)
The global neurovascular devices market is projected to reach tens of billions of USD. Penumbra's growth strategy is to expand its market share within this substantial TAM.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio
- Strong clinical data
- Established relationships with physicians
- Focus on minimally invasive procedures
Weaknesses
- Product recalls and safety concerns in the past
- Reliance on a limited number of products
- High R&D costs
- Regulatory scrutiny
Opportunities
- Expanding into new geographic markets
- Developing new applications for existing technologies
- Acquiring complementary technologies
- Increasing awareness of stroke and vascular diseases
Threats
- Intense competition
- Pricing pressures
- Product liability lawsuits
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- MDT
- STRY
- BSX
Competitive Landscape
Penumbra competes with larger, more established medical device companies. Its focus on innovation and specific niche markets is key to its competitive strategy.
Major Acquisitions
Mederis AG
- Year: 2021
- Acquisition Price (USD millions): 52
- Strategic Rationale: To expand Penumbra's product portfolio in the field of electrosurgical devices for tumor ablation.
Growth Trajectory and Initiatives
Historical Growth: Penumbra has experienced significant revenue growth driven by adoption of its products.
Future Projections: Analysts generally project continued revenue growth for Penumbra, driven by expansion into new markets and product innovation.
Recent Initiatives: Recent initiatives include new product launches, clinical trials, and expansion of sales and marketing efforts.
Summary
Penumbra is a growing medical device company focusing on neurovascular and peripheral vascular interventions. While it faces competition and regulatory scrutiny, its innovative products and strong clinical data provide a solid foundation for future growth. Monitoring market dynamics and adapting to reimbursement changes are crucial. Financial stability depends on managing R&D costs and mitigating risks associated with product safety.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry reports
- Press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data accuracy is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Penumbra Inc
Exchange NYSE | Headquaters Alameda, CA, United States | ||
IPO Launch date 2015-09-18 | Co-Founder, Chairman, President & CEO Mr. Adam Elsesser J.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 4500 | Website https://www.penumbrainc.com |
Full time employees 4500 | Website https://www.penumbrainc.com | ||
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.